Virtual Network's Login.
Chairs : T. Barbui , A. R. Green, R. Levine, H. L. Pahl, R. Skoda, W Vainchenker, A. Vannucchi
SESSION I:
Causes of myeloproliferative neoplasms – M.–F. McMullin
SESSION II:
Stem cell directed therapies for MPN patients – R. Hoffman
The Recql5 helicase, a novel downstream target of JAK2V617F – A. Mullally
Haemostasis disorders in JAK2V617F knock-in mice – J.-L. Villeval
Prognostic impact of mutations in myelofibrosis – A. Vannucchi
SESSION IV:
JAK-STAT signaling in MPNs – V. Sexl
Efficacy and toxicity of JAK inhibitors – C. Harrison
Conventional and newer prognostic factors in myelofibrosis – F. Cervantes
SESSION V:
How do we achieve more meaningful responses to MPN therapy? – R. Mesa
MPL/JAK2: from one signaling pathway to several disorders – I. Plo
